Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Moderate Buy” from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $30.20.

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, January 21st. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a report on Monday, December 15th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Arcus Biosciences in a research report on Monday, March 2nd. Bank of America increased their price target on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a research report on Thursday, January 8th.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $20.23 on Wednesday. The stock has a market capitalization of $2.54 billion, a PE ratio of -6.13 and a beta of 0.85. The business’s 50 day simple moving average is $21.51 and its 200 day simple moving average is $19.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.36 and a quick ratio of 4.36. Arcus Biosciences has a one year low of $6.50 and a one year high of $26.40.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.22. The firm had revenue of $33.00 million during the quarter, compared to analyst estimates of $24.94 million. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 65.77%. The company’s revenue was down 8.3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.03) EPS. As a group, research analysts forecast that Arcus Biosciences will post -3.15 earnings per share for the current year.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, President Juan C. Jaen sold 31,823 shares of Arcus Biosciences stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $21.41, for a total value of $681,330.43. Following the completion of the sale, the president directly owned 922,240 shares in the company, valued at approximately $19,745,158.40. The trade was a 3.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert C. Goeltz II sold 6,552 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $23.38, for a total value of $153,185.76. Following the completion of the transaction, the chief financial officer directly owned 67,924 shares in the company, valued at approximately $1,588,063.12. This trade represents a 8.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of RCUS. Hantz Financial Services Inc. boosted its stake in Arcus Biosciences by 121.9% during the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after acquiring an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Arcus Biosciences in the fourth quarter worth $39,000. GAMMA Investing LLC increased its stake in Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after purchasing an additional 2,845 shares during the period. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of Arcus Biosciences during the third quarter valued at about $69,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.